Copyright
©The Author(s) 2023.
World J Psychiatry. Sep 19, 2023; 13(9): 630-644
Published online Sep 19, 2023. doi: 10.5498/wjp.v13.i9.630
Published online Sep 19, 2023. doi: 10.5498/wjp.v13.i9.630
Table 2 miRNA levels by groups of more and less severe symptoms of cognitive impairment or depress in cerebral small vessel disease patients, n (%)
Assessment Scale | More severe disease (below the average score) | Less severe disease (beyond the average score) | P value of miRNA-levels | ||
Patients | miRNA level | Patients | miRNA level | ||
MoCA | 45 (56.25) | 1.18 ± 0.32 | 35 (43.75) | 2.15 ± 0.45 | 0.010 |
EFA | 40 (50) | 1.25 ± 0.40 | 40 (50) | 2.30 ± 0.50 | 0.0092 |
HAMD | 50 (62.5) | 1.10 ± 0.35 | 30 (37.5) | 2.20 ± 0.55 | 0.030 |
BDI | 38 (47.5) | 1.15 ± 0.38 | 42 (52.5) | 2.25 ± 0.48 | 0.0012 |
- Citation: Wang Z, Li XN, Yang SN, Wang Y, Gao KJ, Han B, Ma AJ. Exosomal miR-320e through wnt2targeted inhibition of the Wnt/β-catenin pathway allevisate cerebral small vessel disease and cognitive impairment. World J Psychiatry 2023; 13(9): 630-644
- URL: https://www.wjgnet.com/2220-3206/full/v13/i9/630.htm
- DOI: https://dx.doi.org/10.5498/wjp.v13.i9.630